Edgewise Therapeutics Inc
For the period ended Dec 31, 2023. Filed Feb 22, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 22, 2024
EWTX$48.74+8.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
BALANCE SHEETS
(In thousands, except share and per share data)
| | | | | | | |
|---|---|---|---|---|---|---|
| · · As of · · As of | ||||||
| · · December 31, · · December 31, | ||||||
| · 2023 · 2022 | ||||||
| Assets · · · · | ||||||
| Current assets · · · | ||||||
| Cash and cash equivalents | | $86,097 | $21,993 | |||
| Marketable securities, available for sale | | 232,296 | | 329,954 | ||
| Prepaid expenses and other assets | | 8,604 | | 5,052 | ||
| Total current assets | | 326,997 | | 356,999 | ||
| | | | | | | |
| Property and equipment, net | | 10,443 | | 8,533 | ||
| Operating lease right-of-use asset | | | 2,247 | | | 1,318 |
| Other non-current assets | | 348 | | 251 | ||
| | | | | | | |
| Total assets | | $340,035 | | $367,101 | ||
| | | | | | | |
| Liabilities and stockholders' equity | | | ||||
| | | | | | | |
| Current liabilities | | | | |||
| Accounts payable | | $4,025 | | $6,105 | ||
| Accrued compensation | | 5,695 | | 4,032 | ||
| Accrued other expenses | | 6,071 | | 5,840 | ||
| Operating lease liability, current portion | | | 980 | | | 608 |
| Total current liabilities | | 16,771 | | 16,585 | ||
| Operating lease liability, net of current portion | | | 4,434 | | | 3,800 |
| | | | | | | |
| Total liabilities | | 21,205 | | 20,385 | ||
| | | | | | | |
| Commitments and contingencies (see note 5) | | | | |||
| | | | | | | |
| Stockholders' equity: | | | ||||
| Preferred stock, $.0001 par value per share; 200,000,000 shares authorized and no shares issued or outstanding as of December 31, 2023 and December 31, 2022 | | | — | | | — |
| Common stock, $.0001 par value per share; 1,000,000,000 shares authorized as of December 31, 2023 and December 31, 2022; 70,453,342 shares and 63,257,376 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively | | 7 | | 6 | ||
| Additional paid-in capital | | 563,487 | | 492,665 | ||
| Accumulated other comprehensive income (loss) | | | 99 | | | (1,355) |
| Accumulated deficit | | (244,763) | | (144,600) | ||
| Total stockholders' equity | | 318,830 | | 346,716 | ||
| | | | | | | |
| Total liabilities and stockholders' equity | | $340,035 | | $367,101 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.